Hot Investor Mandate: Korea Investment Firm Seeks Novel Oncology, Immunology, Rare Disease Drugs & Platform Technologies in Pre-Clinical/Early Clinical Stage

9 May

An investment and management company headquartered in South Korea has ~$500M assets under management, and has a strong product/partnership portfolio in oncology, cardiovascular, CNS, anti-infection, among others. The firm has invested in an early-stage cell therapy company in South Korea, and is actively seeking early-stage (Seed to Series A) investment opportunities, and will also consider investments into VC funds that have aligned interest areas. The firm seeks to invest between $1-2M with capacity for up to $5M per company for initial investment, with potential for follow-on investments for promising companies that achieve milestones. The firm is actively seeking for global opportunities.

The firm is most interested in companies developing novel drugs in oncology, immunology, and rare disease indications and/or novel platform technologies for drug development. The firm will consider different types of modalities but is most interested in small molecules and biologics. In terms of stage of development, the firm is most interested in pre-clinical or early clinical stage companies.

The firm has a preference for working with experienced management teams – significant experience in drug development or senior management in global pharma or large biotech is considered a huge plus. The firm highly prefers companies that have a strong IP portfolio.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: